Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

被引:191
作者
Dumas, Emily O. [1 ]
Pollack, Gary M. [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
opioid; pharmacodynamics; pharmacokinetics; tolerance;
D O I
10.1208/s12248-008-9056-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The opioids are commonly used to treat acute and severe pain. Long-term opioid administration eventually reaches a dose ceiling that is attributable to the rapid onset of analgesic tolerance coupled with the slow development of tolerance to the untoward side effects of respiratory depression, nausea and decreased gastrointestinal motility. The need for effective-long term analgesia remains. In order to develop new therapeutics and novel strategies for use of current analgesics, the processes that mediate tolerance must be understood. This review highlights potential pharmacokinetic (changes in metabolite production, metabolizing enzyme expression, and transporter function) and pharmacodynamic (receptor type, location and functionality; alterations in signaling pathways and cross-tolerance) aspects of opioid tolerance development, and presents several pharmacodynamic modeling strategies that have been used to characterize time-dependent attenuation of opioid analgesia.
引用
收藏
页码:537 / 551
页数:15
相关论文
共 118 条
  • [1] Allen RM, 2000, J PHARMACOL EXP THER, V295, P1012
  • [2] [Anonymous], 1996, CATALOGUE HLTH INDIC, P1
  • [3] Aquilante CL, 1999, LIFE SCI, V66, pPL47
  • [4] Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations
    Athanasos, P
    Smith, CS
    White, JM
    Somogyi, AA
    Bochner, F
    Ling, W
    [J]. PAIN, 2006, 120 (03) : 267 - 275
  • [5] NITRIC-OXIDE AND OPIOID TOLERANCE
    BABEY, AM
    KOLESNIKOV, Y
    CHENG, J
    INTURRISI, CE
    TRIFILLETTI, RR
    PASTERNAK, GW
    [J]. NEUROPHARMACOLOGY, 1994, 33 (11) : 1463 - 1470
  • [6] Bailey CP, 2003, J NEUROSCI, V23, P10515
  • [7] THE EXCITATORY EFFECTS OF MORPHINE-3-GLUCURONIDE ARE ATTENUATED BY LY274614, A COMPETITIVE NMDA RECEPTOR ANTAGONIST, AND BY MIDAZOLAM, AN AGONIST AT THE BENZODIAZEPINE SITE ON THE GABA(A) RECEPTOR COMPLEX
    BARTLETT, SE
    CRAMOND, T
    SMITH, MT
    [J]. LIFE SCIENCES, 1994, 54 (10) : 687 - 694
  • [8] In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation
    Bauer, Bjorn
    Yang, Xiaodong
    Hartz, Anika M. S.
    Olson, Emily R.
    Zhao, Rong
    Kalvass, J. Cory
    Pollack, Gary M.
    Miller, David S.
    [J]. MOLECULAR PHARMACOLOGY, 2006, 70 (04) : 1212 - 1219
  • [9] A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signaling
    Befort, K
    Filliol, D
    Décaillot, FM
    Gavériaux-Ruff, C
    Hoehe, MR
    Kieffer, BL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) : 3130 - 3137
  • [10] BERKOWITZ B A, 1976, Clinical Pharmacokinetics, V1, P219, DOI 10.2165/00003088-197601030-00004